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In a recent study in Nature Biotechnology, Tang et al. (2011) describe a new marker of pluripotency, stage-
specific embryonic antigen-5 (SSEA-5), and show that this oligosaccharide, together with two other surface
antigens, can be used to remove all tumor-initiating cells from prospective cell transplants.The two characteristics of self-renewal
and pluripotency inherent to human plu-
ripotent stem cells (hPSCs), including
embryonic stem cells (hESCs) and
induced pluripotent stem cells (iPSCs),
which make them an attractive source for
cell-replacement therapies, unfortunately
also raise concerns of tumorigenicity.
The tumorigenic propensity of stem cells
imposes a major obstacle to the explora-
tion of their full clinical potential. Tang
et al. (2011) suggested an approach that
has broad implications: the prospective
removal of tumor-initiating cells via im-
munodepletion. They identified a new sur-
face marker, stage-specific embryonic
antigen-5 (SSEA-5), a glycan highly ex-
pressed by hPSCs. Using an antibody
created against SSEA-5 in conjunction
with antibodies against two other surface
antigens, Tang and colleagues were able
to completely deplete the tumor-initiating
cells from mixtures of partially differenti-
ated cells.
Tumor development occurs when
residual undifferentiated PSCs are trans-
planted and subsequently form tera-
tomas, benign tumors that contain repre-
sentatives of the three embryonic germ
layers (ectoderm, endoderm, and meso-
derm) in various ratios. Very rarely, when
differentiated cells undergo transforma-
tion during culture adaptation, potentially
more aggressive tumors can emerge:
teratocarcinomas, the malignant counter-
part of teratomas (Ben-David and Benve-
nisty, 2011).
Teratoma formation usually inversely
correlates with predifferentiation culture
time; however, there is no guarantee that
prolonged in vitro culture of hPSCs willcompletely eliminate the risk of tumor
formation. The latter depends on the type
of cells (hESCs versus hiPSCs), the differ-
entiation protocol employed, the anatom-
ical site of transplantation, and the host
immune interaction with the transplanted
cells. Moreover, the fact that only a small
number of pluripotent cells are needed to
produce teratomas poses a significant
challenge for obtaining cell or tissue trans-
plants entirely free of tumor-initiating cells
(Hentze et al., 2009).
Strategies that may help overcome the
tumorigenic risk of hPSCs can be divided
into two major categories. The first treats
tumor-prone cells after their transplanta-
tion or after detection of tumor develop-
ment. This strategy requires the introduc-
tion of ‘‘suicide’’ genes (thymidine kinase)
into the cells, and the administration of
specific drugs such as the antiviral ganci-
clovir to activate and eliminate the tumor
in the patient (Schuldiner et al., 2003). In
addition to the drawback of treating these
types of tumors after they have already
formed, the use of genetically modified
cells raises the risk for cell transformation
and possible cytotoxic effects of the
drug on nontumorigenic cells. Another
approach, which also requires genetic
manipulation of the cells, ablates the
oncogenes involved in teratoma formation
(e.g., via survivin), or interferes with genes
that are essential for the self-renewal of
PSCs such as MYC, thus decreasing their
tumorigenic potential (Ben-David and
Benvenisty, 2011).
A second and seemingly more practical
strategy for overcoming the tumorigenic
risk of hPSCs is based on the prevention
of transplantation of tumor-forming cells.Cell Stem CellThis can be achieved by transplantation
of a pure population of terminally differen-
tiated cells or by complete ablation of
undifferentiated or partially differentiated
cells frommixedpopulations before trans-
plantation. Targeted elimination of plurip-
otent cells has been attempted by cyto-
toxic monoclonal antibodies (mAbs) (Tan
et al., 2009). Cells have also been sorted
on the basis of pluripotent-specific cell
surface markers (Fong et al., 2009).
However, none of the currently available
methods were able to absolutely deplete
residual tumor-initiating cells from hetero-
geneous differentiated cultures.
Tang et al. (2011) present a technical
advancement to address the problem.
By means of immunodepletion with mAbs
against human pluripotency surface
markers (PSMs), they were able to remove
residual teratoma-initiating cells from
heterogeneous populations of differenti-
ated cultures before transplantation into
a mouse model. To identify a suitable
surface-marker that could be used to this
end, the authors exploited various mAb
sources, including a mouse hybridoma
library raised against undifferentiated
hESCs. From this library, onemAb, namely
anti-SSEA-5, identified a highly specific
surfacemarker in cultured undifferentiated
hPSCs, and also in the inner cell mass
of the human blastocyst in vivo. Anti-
SSEA-5 specificity was confirmed by
comparing the transcription of pluripo-
tency genes OCT4, NANOG, and SOX2 in
sorted SSEA-5+ relative to SSEA-5 cells,
following a 3 day treatment with retinoic
acid or BMP4. Differentiation also resulted
in reduction by two to three orders ofmag-
nitude of the SSEA-5 signal, significantly9, October 7, 2011 ª2011 Elsevier Inc. 291
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Previewsmore than that of other classical oligosac-
charide surface antigens SSEA-4, SSEA-3,
and TRA-1-81. Glycan arrays identified
SSEA-5 as an H type-1 (H-1) antigen, a
glycan capable of O- andN-linkage to sur-
face proteins with expression on mem-
brane lipids.
Glycans are highly expressed by hPSCs
and their early progeny. A switch of the
core structures of glycans (from globo-
and lacto- to ganglio-series) during hESC
differentiation has recently been reported
(Liang et al., 2010). Indeed, Tang et al.
discovered that the glycan backbone
shifts from type 1 [H-1 and Lewis (a)] to
type 2 (H-2 and CD15/SSEA-1) during
differentiation. Underlying this switch are
changes in galactosyl, glucosaminyl, and
glycosyl transferase expression, which
also result in the loss of SSEA-3 and
SSEA-4, and gain of SSEA-1 antigen.
The newly discovered SSEA-5 glycan
and the dynamic shifts in the structures
of glycans during differentiationmay serve
as a platform to delineate factors govern-
ing pluripotency and to identify the func-
tional role of glycans during early human
development. This is especially important
in light of the observation that hESCsare in
a metastable state and can be epigeneti-
cally reprogrammed during culture adap-
tation (Hanna et al., 2010) from an epiblast
state (expressing the abovementioned
oligosaccharides SSEA-3, SSEA-4, and
SSEA-5) to a more ‘‘naı¨ve’’ undifferenti-
ated mouse-ESC-like state (expressing
SSEA-1) (Buecker et al., 2010). These plu-
ripotency transition states must be con-
sideredwhendesigning a panel of glycans
and other surface markers for character-
izing and sorting hPSC subpopulations.
In functional in vivo assays, where cell
mixtures of terminally differentiated and
undifferentiated hESCs (at a 100:1 ratio)292 Cell Stem Cell 9, October 7, 2011 ª2011were depleted of SSEA5+ cells prior to
transplantation into immunedeficient
mice, the incidence and size of teratoma
formationwas greatly reduced.Moreover,
Tang et al. were able to completely elimi-
nate the teratoma-forming cells by adding
two additional PSMs (i.e., SSEA-5/CD9/
CD90 or SSEA-5/CD50/CD200) that are
rarely expressed together in nonpluripo-
tent cells. This observation suggests that
a fraction of SSEA-5-depleted cells may
have not concluded their exit from plurip-
otency and may therefore require detec-
tion and removal by additional PSMs.
It seems that complete elimination of all
undifferentiated or partially differentiated
cells from amixed culture by the immuno-
depletion approach will not be easily
achieved, and may require further devel-
opment. Though the approach by Tang
et al. may expedite this process, it
requires enzymatic dissociation of the
prospective cells or tissues into a single-
cell suspension to enable sorting of the
undesired cells before transplantation.
This hurdle is expected to be even greater
if the final cellular product is an engi-
neered tissue. To circumvent the need to
dissociate the differentiated cells and
tissues, it may be possible to assay the
existence of residual teratoma-initiating
cells by sampling and transplanting the
end-products in animals, assuming that
the samples indeed represent all cells or
tissues intended for patient use. The
PSM panel will also likely require further
optimization, keeping in mind cell marker
kinetics during differentiation, in order to
avoid interfering with the differentiation
processes, and to prevent the removal
of desired cells expressing key PSMs.
With the launch of the first clinical trials
of hESC-derived cellular therapies, the
application of hESCs in regenerativeElsevier Inc.medicine is becoming a reality. Ongoing
clinical efforts draw attention to practical
measures that will provide a reasonable
assurance of safety, with particular
emphasis on the prevention of tumor
formation (Goldring et al., 2011). Taken
in this context, the study by Tang et al.
(2011) presents a critical advance that
could provide promising avenues for
future clinical application.REFERENCES
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